The Experts below are selected from a list of 52236 Experts worldwide ranked by ideXlab platform
Greepol Manwiwattanakul - One of the best experts on this subject based on the ideXlab platform.
-
Release Profile comparison and stability of diltiazem resin microcapsules in sustained Release suspensions
International Journal of Pharmaceutics, 2008Co-Authors: Varaporn Buraphacheep Junyaprasert, Greepol ManwiwattanakulAbstract:Abstract A sustained Release suspension of diltiazem, a short half-life calcium channel blocker, was developed to reduce frequency of drug administration, ease of dose adjustment and improve patient compliance. In this study, the sustained Release of diltiazem was obtained by complexing the drug with Dowex ® 50W×4 and Dowex ® 50W×8, strong cationic exchange resins with 4% and 8% degree of cross-linking, respectively. The diltiazem–Dowex ® 50W×4 complexes provided the highest drug Release and were subsequently used to prepare the microcapsules by emulsion–solvent evaporation method, using 0.75–5.00% cellulose acetate butyrate (CAB) in methylene chloride as a coating solution. As the concentration of CAB increased, the size of microcapsule increased and the drug Release from the microcapsule was retarded. From Release Profile comparison using f 1 and f 2 factors, it was found that the microcapsules coated with 1.75% CAB provided a Release Profile equivalent to the commercial product of diltiazem sustained Release capsule, Herbesser ® 90SR. Furthermore, sustained Release suspensions of the diltiazem microcapsules were formulated with the use of 0.8% sodium carboxymethylcellulose or 0.4% xanthan gum as a suspending agent. The suspension of 0.4% xanthan gum showed superior in physical appearance after 120-day storage at 30 and 45 °C. In addition, all sustained Release suspensions possessed good stability with low drug leaching and their Release Profiles were unchanged when compared with the dried microcapsules for 120 days at 30 and 45 °C.
-
Release Profile comparison and stability of diltiazem-resin microcapsules in sustained Release suspensions.
International journal of pharmaceutics, 2007Co-Authors: Varaporn Buraphacheep Junyaprasert, Greepol ManwiwattanakulAbstract:A sustained Release suspension of diltiazem, a short half-life calcium channel blocker, was developed to reduce frequency of drug administration, ease of dose adjustment and improve patient compliance. In this study, the sustained Release of diltiazem was obtained by complexing the drug with Dowex 50W x 4 and Dowex 50W x 8, strong cationic exchange resins with 4% and 8% degree of cross-linking, respectively. The diltiazem-Dowex 50W x 4 complexes provided the highest drug Release and were subsequently used to prepare the microcapsules by emulsion-solvent evaporation method, using 0.75-5.00% cellulose acetate butyrate (CAB) in methylene chloride as a coating solution. As the concentration of CAB increased, the size of microcapsule increased and the drug Release from the microcapsule was retarded. From Release Profile comparison using f(1) and f(2) factors, it was found that the microcapsules coated with 1.75% CAB provided a Release Profile equivalent to the commercial product of diltiazem sustained Release capsule, Herbesser 90SR. Furthermore, sustained Release suspensions of the diltiazem microcapsules were formulated with the use of 0.8% sodium carboxymethylcellulose or 0.4% xanthan gum as a suspending agent. The suspension of 0.4% xanthan gum showed superior in physical appearance after 120-day storage at 30 and 45 degrees C. In addition, all sustained Release suspensions possessed good stability with low drug leaching and their Release Profiles were unchanged when compared with the dried microcapsules for 120 days at 30 and 45 degrees C.
Eliana B. Souto - One of the best experts on this subject based on the ideXlab platform.
-
predictive modeling of insulin Release Profile from cross linked chitosan microspheres
European Journal of Medicinal Chemistry, 2013Co-Authors: S Jose, Eliana B. Souto, Joana F Fangueiro, J Smitha, T A Cinu, A J Chacko, K PremalethaAbstract:Abstract Insulin-loaded microspheres composed of chitosan 3% (w/v), and loading 120 IU insulin were produced by emulsion cross-linking method. Cross-linking time was 5 h and glutaraldehyde 3.5% (v/v) was used as cross-linker. Swelling ratio studies were evaluated to predict Release of insulin from chitosan microspheres. Bacitracin and sodium taurocholate were incorporated in the formulations as proteolytic enzyme inhibitor and absorption enhancer, respectively. In vitro insulin Release studies were performed in phosphate buffer pH 7.4 and also in HCl pH 2 with and without trypsin. Activity of bacitracin was also evaluated. In vitro Release showed a controlled Profile up to 12 h and the formulation containing 0.15% (w/v) of bacitracin revealed a maximum biological activity of about 49.1 ± 4.1%. Mathematical modeling using Higuchi and Korsmeyer–Peppas suggested a non-Fickian diffusion as the mechanism of insulin Release. Insulin-loaded chitosan microspheres for oral delivery showed to be an innovative and reliable delivery system to overcome conventional insulin therapy.
-
Release Profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers ta nlc in vitro and ex vivo studies
Nanomedicine: Nanotechnology Biology and Medicine, 2012Co-Authors: Joana Araujo, Eliana B. Souto, Maria Luisa Garcia, Mireia Mallandrich, Ana C CalpenaAbstract:Abstract Nanostructured lipid carriers (NLC) have been developed for sustained Release of triamcinolone acetonide (TA), a corticosteroid commonly indicated for macular edema, neovascularization, and other ocular inflammatory disorders. TA-NLC were prepared by high-pressure homogenization and characterized for in vitro Release by dialysis bag. Ex vivo permeation Profile was assessed using rabbit sclera isolated and mounted in Franz diffusion cells. TA-NLC were placed in episcleral donor compartment and choroidal side was perfused with HEPES buffer. Tissue sections underwent drug wash-out, following analysis by validated RP-HPLC of drug content and perfused fractions collected over 24 hours. Drug Release followed one-order kinetics and permeability studies confirmed that TA is able to diffuse across rabbit sclera in sustained Profile, following zero-order kinetics. Strong tissue binding was observed, providing a drug depot. These findings are of potential use when designing future TA therapy strategies for ocular diseases of posterior segment. From the Clinical Editor In this study of triamcinolone acetonide loaded nanosize lipid carriers, potential ophthalmological applications are investigated including its trans-scleral permeation and Release Profile. Future in vitro studies are anticipated to establish this novel lipid carrier as a future therapeutic option for ocular diseases of the posterior segment.
-
preparation of gastro resistant pellets containing chitosan microspheres for improvement of oral didanosine bioavailability
Journal of Pharmaceutical Analysis, 2012Co-Authors: Patricia Severino, George Gualberto Gualter De Oliveira, Eliana B. Souto, Humberto Gomes Ferraz, Maria Helena Andrade SantanaAbstract:The purpose of this work was to introduce a new concept of coated pellets containing chitosan microspheres loaded with didadosine for oral administration, aiming at reducing the frequency of administration and improving the bioavailability by a suitable Release Profile. Chitosan microspheres were produced under fluidized bed, followed by extrusion and spheronization to obtain pellets with a mean diameter of about 1 mm. The pellets were then coated with Kollidon® VA64 and Kollicoat® MAE100P in water dispersion to depict a sustained Release Profile. Conventional hard gelatine capsules were loaded with these pellets and tested in vitro for their Release Profile of didadosine. Dissolution testing confirmed that chitosan microsphere pellets provides appropriate sustained Release up to 2 h behavior for didanosine.
Varaporn Buraphacheep Junyaprasert - One of the best experts on this subject based on the ideXlab platform.
-
Release Profile comparison and stability of diltiazem resin microcapsules in sustained Release suspensions
International Journal of Pharmaceutics, 2008Co-Authors: Varaporn Buraphacheep Junyaprasert, Greepol ManwiwattanakulAbstract:Abstract A sustained Release suspension of diltiazem, a short half-life calcium channel blocker, was developed to reduce frequency of drug administration, ease of dose adjustment and improve patient compliance. In this study, the sustained Release of diltiazem was obtained by complexing the drug with Dowex ® 50W×4 and Dowex ® 50W×8, strong cationic exchange resins with 4% and 8% degree of cross-linking, respectively. The diltiazem–Dowex ® 50W×4 complexes provided the highest drug Release and were subsequently used to prepare the microcapsules by emulsion–solvent evaporation method, using 0.75–5.00% cellulose acetate butyrate (CAB) in methylene chloride as a coating solution. As the concentration of CAB increased, the size of microcapsule increased and the drug Release from the microcapsule was retarded. From Release Profile comparison using f 1 and f 2 factors, it was found that the microcapsules coated with 1.75% CAB provided a Release Profile equivalent to the commercial product of diltiazem sustained Release capsule, Herbesser ® 90SR. Furthermore, sustained Release suspensions of the diltiazem microcapsules were formulated with the use of 0.8% sodium carboxymethylcellulose or 0.4% xanthan gum as a suspending agent. The suspension of 0.4% xanthan gum showed superior in physical appearance after 120-day storage at 30 and 45 °C. In addition, all sustained Release suspensions possessed good stability with low drug leaching and their Release Profiles were unchanged when compared with the dried microcapsules for 120 days at 30 and 45 °C.
-
Release Profile comparison and stability of diltiazem-resin microcapsules in sustained Release suspensions.
International journal of pharmaceutics, 2007Co-Authors: Varaporn Buraphacheep Junyaprasert, Greepol ManwiwattanakulAbstract:A sustained Release suspension of diltiazem, a short half-life calcium channel blocker, was developed to reduce frequency of drug administration, ease of dose adjustment and improve patient compliance. In this study, the sustained Release of diltiazem was obtained by complexing the drug with Dowex 50W x 4 and Dowex 50W x 8, strong cationic exchange resins with 4% and 8% degree of cross-linking, respectively. The diltiazem-Dowex 50W x 4 complexes provided the highest drug Release and were subsequently used to prepare the microcapsules by emulsion-solvent evaporation method, using 0.75-5.00% cellulose acetate butyrate (CAB) in methylene chloride as a coating solution. As the concentration of CAB increased, the size of microcapsule increased and the drug Release from the microcapsule was retarded. From Release Profile comparison using f(1) and f(2) factors, it was found that the microcapsules coated with 1.75% CAB provided a Release Profile equivalent to the commercial product of diltiazem sustained Release capsule, Herbesser 90SR. Furthermore, sustained Release suspensions of the diltiazem microcapsules were formulated with the use of 0.8% sodium carboxymethylcellulose or 0.4% xanthan gum as a suspending agent. The suspension of 0.4% xanthan gum showed superior in physical appearance after 120-day storage at 30 and 45 degrees C. In addition, all sustained Release suspensions possessed good stability with low drug leaching and their Release Profiles were unchanged when compared with the dried microcapsules for 120 days at 30 and 45 degrees C.
Sanjay Mathur - One of the best experts on this subject based on the ideXlab platform.
-
drug Release Profile in core shell nanofibrous structures
Computer Methods and Programs in Biomedicine, 2014Co-Authors: Mahboubeh Maleki, Mohammad Amanitehran, Masoud Latifi, Sanjay MathurAbstract:Release Profile of drug constituent encapsulated in electrospun core-shell nanofibrous mats was modeled by Peppas equation and artificial neural network. Core-shell fibers were fabricated by co-axial electrospinning process using tetracycline hydrochloride (TCH) as the core and poly(l-lactide-co-glycolide) (PLGA) or polycaprolactone (PCL) as the shell materials. The density and hydrophilicity of the shell polymers, feed rates and concentrations of core and shell phases, the contribution of TCH in core material and electrical field were the parameters fed to the perceptron network to predict Peppas constants in order to derive Release pattern. This study demonstrated the viability of the prediction tool in determining drug Release Profile of electrospun core-shell nanofibrous scaffolds.
Mahboubeh Maleki - One of the best experts on this subject based on the ideXlab platform.
-
drug Release Profile in core shell nanofibrous structures
Computer Methods and Programs in Biomedicine, 2014Co-Authors: Mahboubeh Maleki, Mohammad Amanitehran, Masoud Latifi, Sanjay MathurAbstract:Release Profile of drug constituent encapsulated in electrospun core-shell nanofibrous mats was modeled by Peppas equation and artificial neural network. Core-shell fibers were fabricated by co-axial electrospinning process using tetracycline hydrochloride (TCH) as the core and poly(l-lactide-co-glycolide) (PLGA) or polycaprolactone (PCL) as the shell materials. The density and hydrophilicity of the shell polymers, feed rates and concentrations of core and shell phases, the contribution of TCH in core material and electrical field were the parameters fed to the perceptron network to predict Peppas constants in order to derive Release pattern. This study demonstrated the viability of the prediction tool in determining drug Release Profile of electrospun core-shell nanofibrous scaffolds.
